ES2296786T3 - Composicion catartica. - Google Patents

Composicion catartica. Download PDF

Info

Publication number
ES2296786T3
ES2296786T3 ES01961333T ES01961333T ES2296786T3 ES 2296786 T3 ES2296786 T3 ES 2296786T3 ES 01961333 T ES01961333 T ES 01961333T ES 01961333 T ES01961333 T ES 01961333T ES 2296786 T3 ES2296786 T3 ES 2296786T3
Authority
ES
Spain
Prior art keywords
compound
present
composition
use according
triglyceride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES01961333T
Other languages
English (en)
Spanish (es)
Inventor
Ryuji Ueno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sucampo GmbH
Original Assignee
Sucampo GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24630250&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2296786(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sucampo GmbH filed Critical Sucampo GmbH
Application granted granted Critical
Publication of ES2296786T3 publication Critical patent/ES2296786T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
ES01961333T 2000-09-05 2001-09-04 Composicion catartica. Expired - Lifetime ES2296786T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US655760 2000-09-05
US09/655,760 US6414016B1 (en) 2000-09-05 2000-09-05 Anti-constipation composition

Publications (1)

Publication Number Publication Date
ES2296786T3 true ES2296786T3 (es) 2008-05-01

Family

ID=24630250

Family Applications (2)

Application Number Title Priority Date Filing Date
ES01961333T Expired - Lifetime ES2296786T3 (es) 2000-09-05 2001-09-04 Composicion catartica.
ES07016834T Expired - Lifetime ES2347697T3 (es) 2000-09-05 2001-09-04 Composicion catartica.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES07016834T Expired - Lifetime ES2347697T3 (es) 2000-09-05 2001-09-04 Composicion catartica.

Country Status (25)

Country Link
US (7) US6414016B1 (https=)
EP (2) EP1857105B1 (https=)
JP (3) JP2004508327A (https=)
KR (2) KR100918223B1 (https=)
CN (1) CN100335049C (https=)
AR (2) AR030609A1 (https=)
AT (1) ATE476975T1 (https=)
AU (2) AU2001282615B2 (https=)
BR (1) BRPI0114042B8 (https=)
CA (1) CA2419741C (https=)
CZ (1) CZ304740B6 (https=)
DE (2) DE60142810D1 (https=)
DK (2) DK1857105T3 (https=)
ES (2) ES2296786T3 (https=)
HU (1) HU229319B1 (https=)
IL (2) IL154534A0 (https=)
MX (1) MXPA03001959A (https=)
NL (1) NL300757I1 (https=)
NO (1) NO332701B1 (https=)
NZ (1) NZ524401A (https=)
PT (2) PT1315485E (https=)
RU (1) RU2694361C3 (https=)
TW (1) TWI305147B (https=)
WO (1) WO2002020007A1 (https=)
ZA (1) ZA200301673B (https=)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0014869B8 (pt) * 1999-10-15 2021-05-25 Sucampo Ag prostaglandinas bicíclicas, composições estabilizadas das mesmas, bem como processo para sua estabilização
US6414016B1 (en) * 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
TWI302100B (en) * 2001-05-02 2008-10-21 Sucampo Ag Composition for treating drug-induced constipation
AR037524A1 (es) 2001-11-14 2004-11-17 Sucampo Ag Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
TWI263505B (en) * 2001-11-19 2006-10-11 Sucampo Ag Pharmaceutical composition comprising a C1C-2 channel opener
NZ539582A (en) * 2002-10-23 2007-07-27 Sucampo Ag Prostaglandin compounds for the treatment of obesity
EP1575596B1 (en) * 2002-12-27 2016-06-22 Sucampo AG Derivatives of prostaglandins for treating irritable bowel syndrome and/or functional dyspepsia
DE602004030245D1 (de) * 2003-07-03 2011-01-05 Sucampo Ag Pharmazeutische magensaftresistent überzogene zusammensetzung enthaltend prostaglandin-analoga als chloridkanalöffner
TWI495471B (zh) * 2003-08-12 2015-08-11 R Tech Ueno Ltd 促進毛髮生長之組成物及方法
RU2392941C2 (ru) * 2004-09-02 2010-06-27 Сукампо Аг Производные простагландинов для лечения желудочно-кишечного нарушения
TWI387454B (zh) * 2004-09-02 2013-03-01 蘇坎波公司 治療胃腸道疾病之方法及組成物
US8202909B2 (en) * 2005-01-27 2012-06-19 Sucampo Ag Method for treating central nervous system disorders
KR20160120809A (ko) * 2005-03-04 2016-10-18 수캄포 아게 말초 혈관 질환 치료를 위한 방법 및 조성물
ES2714198T3 (es) * 2005-03-07 2019-05-27 Univ Chicago Uso de antagonistas opioideos para atenuar la proliferación y la migración de células endoteliales
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US20060281818A1 (en) 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
RU2468800C2 (ru) * 2005-04-12 2012-12-10 Сукампо Аг Комбинированное применение производного простагландина и ингибитора протонового насоса для лечения желудочно-кишечных заболеваний
JP5265369B2 (ja) 2006-01-24 2013-08-14 株式会社アールテック・ウエノ 二環式化合物を含む医薬組成物およびその二環式化合物の安定化方法
KR101437302B1 (ko) * 2006-02-07 2014-09-02 가부시키가이샤 아루떼꾸 우에노 프로스타글란딘 유도체의 제조 방법
US20090012165A1 (en) * 2007-07-03 2009-01-08 Sucampo Ag Pharmaceutical combination of nsaid and prostaglandin compound
US20090030072A1 (en) * 2007-07-03 2009-01-29 Sucampo Ag Pharmaceutical combination of opioid and prostaglandin compound
US20090082442A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched lubiprostone
CN101318948B (zh) * 2008-04-01 2011-04-27 上海天伟生物制药有限公司 鲁比前列酮晶体、其制备方法及用途
US8513441B2 (en) * 2008-08-29 2013-08-20 Alphora Research Inc. Prostaglandin synthesis and intermediates for use therein
PT2349250T (pt) * 2008-10-31 2017-07-25 Lipid Pharmaceuticals Ehf Ácidos gordos para uso como um medicamento
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
SI2384318T1 (en) 2008-12-31 2018-03-30 Ardelyx, Inc. MEASURES AND PROCEDURES FOR THE INHIBITION OF ANTIPORT INHIBITED BY NHE IN THE TREATMENT OF DISEASES RELATED TO STRENGTH OF FLAMMABILITY OR TRADEMARITY WITH SOLO, AND THE EMISSION OF GASTROINTESTINAL TREATMENT
CA2750487A1 (en) 2009-01-22 2010-07-29 Apotex Pharmachem Inc. Methods of making lubiprostone and intermediates thereof
US9084815B2 (en) * 2009-09-16 2015-07-21 Sucampo Ag Method for treating damage induced by an anti-tumor agent, treating mucositis and treating tumor
AU2010295464B2 (en) * 2009-09-18 2015-11-26 Merck Sharp & Dohme Corp. Use of opioid receptor antagonist for gastrointestinal tract disorders
CA2779736A1 (en) * 2009-11-03 2011-05-12 Bernard Charles Sherman Stable pharmaceutical formulations comprising lubiprostone
CA2784933A1 (en) * 2009-12-18 2011-06-23 Apotex Pharmachem Inc. Processes for the purification of lubiprostone
EP2536705A4 (en) 2010-01-28 2013-08-07 Apotex Pharmachem Inc POLYMORPHIC FORMS OF LUBIPROSTON
MX366293B (es) 2012-08-21 2019-07-04 Ardelyx Inc Compuestos y metodos para inhibir al antipuerto mediado por nhe en el tratamiento de trastornos asociados con la retencion de fluidos o la sobrecarga de sal y trastornos del tracto gastrointestinal.
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
LT2983667T (lt) 2013-04-12 2019-07-10 Ardelyx, Inc. Nhe3 rišantys junginiai ir fosfato pernešimo slopinimo būdai
EP3277274B1 (en) 2015-04-01 2024-06-12 Cedars-Sinai Medical Center Anti-methanogenic lovastatin analogs or derivatives and uses thereof
AR105029A1 (es) * 2015-06-19 2017-08-30 Sucampo Ag Composición farmacéutica que comprende derivado de ácido graso
JP6957610B2 (ja) 2016-10-06 2021-11-02 スキャンポ・アーゲーＳｕｃａｍｐｏ ＡＧ 医薬品用途のための多層ビーズ
CA3049678A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds useful for treating gastrointestinal tract disorders
EA201991676A1 (ru) 2017-01-09 2020-01-30 Арделикс, Инк. Ингибиторы nhe-опосредованного антипорта
CN110494721B (zh) * 2017-04-20 2022-06-24 株式会社岛津制作所 分光光度计
US10422729B1 (en) 2019-03-08 2019-09-24 Biodesix, Inc. Blood sample separation devices and methods

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5720305B2 (https=) 1973-02-28 1982-04-27
US4034003A (en) 1974-04-11 1977-07-05 Ono Pharmaceutical Co., Ltd. 15-Cycloalkyl-prostaglandins
JPS5350141A (en) 1976-10-18 1978-05-08 Ono Pharmaceut Co Ltd Stabilization of prostaglandin and prostaglandin analogues
JPS5391110A (en) 1977-01-20 1978-08-10 Yamanouchi Pharmaceut Co Ltd Novel drug composition for rectal infusion
JPS6022708B2 (ja) 1977-07-14 1985-06-03 小野薬品工業株式会社 プロスタグランジン類似化合物
US4308595A (en) * 1979-12-19 1981-12-29 International Business Machines Corporation Array driver
US4670569A (en) 1981-04-02 1987-06-02 G. D. Searle & Co. 5-fluoro-PGI2 compounds
US4579958A (en) 1983-12-23 1986-04-01 G. D. Searle & Co. 5-fluoro-3-oxa-6,7-didehydro-PGI1 compounds
US4687864A (en) 1983-12-23 1987-08-18 G. D. Searle & Co. 5-fluoro-3-oxa-prostacyclin compounds
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
ES2051862T3 (es) 1987-10-02 1994-07-01 Ueno Seiyaku Oyo Kenkyujo Kk Un metodo para producir un medicamento que tiene un efecto catartico.
US5317032A (en) 1987-10-02 1994-05-31 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandin cathartic
JPH0681728B2 (ja) * 1987-10-02 1994-10-19 株式会社上野製薬応用研究所 下 剤
JP2579193B2 (ja) 1988-07-19 1997-02-05 小野薬品工業株式会社 １６，１６−ジフルオロ−１５−オキソ−１５−デオキシｐｇｅ誘導体
CA2030345C (en) 1989-11-22 1998-12-08 Ryuji Ueno Use of 15-keto-prostaglandin compound for improvement of encephalic function
CA2030346C (en) * 1989-11-22 2000-04-11 Ryuji Ueno Treatment of cardiac dysfunction with 15-keto-prostaglandin compounds
JP2515442B2 (ja) * 1990-05-01 1996-07-10 株式会社上野製薬応用研究所 膵臓疾患処置剤
ATE174221T1 (de) * 1990-05-01 1998-12-15 R Tech Ueno Ltd Behandlung von pankreaskrankheit mit 15-keto- prostaglandin e-derivaten
JP2938579B2 (ja) 1990-12-15 1999-08-23 株式会社上野製薬応用研究所 消化管壁保護剤
CA2150287C (en) 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
US5958876A (en) 1996-06-19 1999-09-28 Novartis Ag Cyclosporin-containing pharmaceutical compositions
AUPO665397A0 (en) * 1997-05-07 1997-05-29 Borody, Thomas Julius Novel therapy for constipation
DE69910183T2 (de) 1998-03-11 2004-06-03 Grelan Pharmaceutical Co., Ltd., Hamura Darmlösliche sprudelnde zusammensetzungen
US6471085B1 (en) 1999-10-04 2002-10-29 Anthony J. Gallo Temperature cup
BRPI0014869B8 (pt) * 1999-10-15 2021-05-25 Sucampo Ag prostaglandinas bicíclicas, composições estabilizadas das mesmas, bem como processo para sua estabilização
AU2001287580A1 (en) * 2000-07-14 2002-01-30 Henkel Kommanditgesellschaft Auf Aktien Hollow bodies with compartments
US6414016B1 (en) * 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition

Also Published As

Publication number Publication date
US20120022152A1 (en) 2012-01-26
US8114890B1 (en) 2012-02-14
US6414016B1 (en) 2002-07-02
NL300757I2 (https=) 2015-12-29
US20140235665A1 (en) 2014-08-21
EP1857105B1 (en) 2010-08-11
DE60142810D1 (de) 2010-09-23
IL154534A0 (en) 2003-09-17
DE60131547T2 (de) 2008-10-23
NO20030996L (no) 2003-05-02
AR100291A2 (es) 2016-09-28
HU229319B1 (en) 2013-10-28
ES2347697T3 (es) 2010-11-03
NO20030996D0 (no) 2003-03-04
RU2694361C3 (ru) 2020-07-20
EP1857105A3 (en) 2008-03-05
CZ304740B6 (cs) 2014-09-17
US8748454B2 (en) 2014-06-10
MXPA03001959A (es) 2003-06-24
NO332701B1 (no) 2012-12-10
BRPI0114042B8 (pt) 2021-05-25
TWI305147B (en) 2009-01-11
HUP0302422A2 (hu) 2003-10-28
EP1315485B1 (en) 2007-11-21
DE60131547D1 (de) 2008-01-03
ATE476975T1 (de) 2010-08-15
NL300757I1 (https=) 2015-12-29
AU2001282615B2 (en) 2006-06-22
PT1315485E (pt) 2008-01-23
EP1315485A1 (en) 2003-06-04
US20030040528A1 (en) 2003-02-27
CN1655776A (zh) 2005-08-17
DK1315485T3 (da) 2008-03-03
US8071613B2 (en) 2011-12-06
DK1857105T3 (da) 2010-09-20
JP2009286806A (ja) 2009-12-10
RU2694361C2 (ru) 2019-07-12
KR20030029919A (ko) 2003-04-16
US20030216465A1 (en) 2003-11-20
AR030609A1 (es) 2003-08-27
RU2694361C9 (ru) 2019-12-25
HUP0302422A3 (en) 2005-02-28
BRPI0114042B1 (pt) 2016-11-08
JP2004508327A (ja) 2004-03-18
CA2419741A1 (en) 2002-03-14
KR100918223B1 (ko) 2009-09-21
ZA200301673B (en) 2003-11-26
PT1857105E (pt) 2010-10-08
WO2002020007A1 (en) 2002-03-14
CN100335049C (zh) 2007-09-05
US20120237598A1 (en) 2012-09-20
KR20080091278A (ko) 2008-10-09
AU8261501A (en) 2002-03-22
JP2009114217A (ja) 2009-05-28
NZ524401A (en) 2004-08-27
CA2419741C (en) 2010-11-30
BR0114042A (pt) 2003-07-22
IL154534A (en) 2010-04-29
US20050222195A1 (en) 2005-10-06
US6610732B2 (en) 2003-08-26
EP1857105A2 (en) 2007-11-21
JP4684334B2 (ja) 2011-05-18
KR100901102B1 (ko) 2009-06-08

Similar Documents

Publication Publication Date Title
ES2296786T3 (es) Composicion catartica.
AU2001282615A1 (en) Cathartic composition
EP2175861B1 (en) Pharmaceutical combination of naproxen with 13,14-dihydro-15-keto-16,16-difluoro-18-methyl-prostaglandin E1
JP2011201905A (ja) 便秘の処置用のプロスタグランジンアナログを含む用量単位
PT1392318E (pt) 15-ceto-prostaglandinas para o tratamento de obstipação induzida por fármacos
ES2591252T3 (es) Derivados de prostaglandinas para tratar el síndrome de colon irritable y/o la dispepsia funcional
NO340989B1 (no) Farmasøytisk sammensetning som omfatter en prostaglandinforbindelse for behandling av forstoppelse for å forbedre livskvaliteten hos et menneske, samt anvendelse av en prostaglandinforbindelse ved fremstilling av en farmasøytisk sammensetning for langtidsbehandling av forstoppelse for å forbedre livskvaliteten hos et menneske.
HK1155649B (en) Dosage unit comprising a prostaglandin analog for treating constipation